ctDNA offers a non-invasive way to track Multiple Myeloma, reducing the need for painful bone marrow biopsies Detects genetic mutations, treatment resistance, and disease progression before ...

In its fourth quarter 2024 investor letter, Brown Advisors Global Leaders Strategy emphasized stocks such as Illumina, Inc. (NASDAQ:ILMN). Illumina, Inc. (NASDAQ:ILMN) offers sequencing- and array ...

Alexander Spira, MD, PhD, FACP, discusses the PAPILLON trial, including its methods, design, and rationale as well as new data from the study. Alexander Spira, MD, PhD, FACP, director of the Virginia ...

At ctDNA levels below 10 mutant copies/mL (0.25% VAF) it can reassure patients that progression is unlikely, while levels above 100 copies/mL (2.5% VAF) are associated with at least a 90% chance ...

Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu 610064, Sichuan, China ...

Follow us on Facebook and join our Telegram channel for the latest updates. Prime Minister and Finance Minister Lawrence Wong mentioned Illumina, the Nasdaq-listed biotechnology firm headquartered in ...

Genome-wide burden survival tests for patients with metastatic prostate cancer on androgen receptor-targeted therapies in the Million Veterans Program dataset. This is an ASCO Meeting Abstract from ...

circulating tumor DNA (ctDNA), which is released into the bloodstream by tumor cells, offers a promising non-invasive alternative. It allows for real-time monitoring and comprehensive genetic ...

Genomic characteristics of patients with metastatic hormone-sensitive prostate cancer treated with ARPI-based therapy: A single-center analysis. Racial differences in organic anion transport proteins ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...